Pharma: Clinic Roundup
Tuesday, July 31, 2012
Bristol-Myers Squibb Co., of New York, and AstraZeneca plc, of London, said results of analyses show that Onglyza (saxagliptin) 5 mg demonstrated improvements across key measures of blood sugar control compared to placebo in adults with Type II diabetes who are at high risk for cardiovascular disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.